A major challenge in manufacturing adherent cells for advanced therapies is producing the large quantities of cells needed in a cost-effective manner. Corning has developed a novel fixed bed bioreactor platform that is designed to deliver:
-Significant surface area intensification and high-yield bioproduction capability.
-Scalability for adherent cell culture expansion from research to production(1 m2 to 1000 m2).
-High yields and viable cell harvest by utilizing an innovative mesh substrate design.
-Flexibility to support multiple cell types and cell and gene therapy applications.
-Process consistency through integration of control and automation capabilities.